srch

XANTUS pooled: global rivaroxaban use in real-world patients with NVAF 2021-02-17 The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe

Background: Non-vitamin K antagonist oral anticoagulants (NOACs) are increasingly used for stroke prevention in atrial fibrillation (AF) but ...

A major strength of the XANTUS pooled analysis is the adjudication of outcome events by a central committee; this contrasts with large claims ...

Results from XANTUS pooled population showed low rates of both stroke and major bleeding with rivaroxaban at 0.9% and 1.7% per year respectively, generally consistent with those in the ROCKET AF trial. The majority (96.1%) of the pooled XANTUS population did not experience stroke / systemic embolism, major bleeding and all-cause death.

A pre-planned pooled analysis of the prospective, observational XANTUS, XANAP and XANTUS-EL studies of unselected patients with AF X AF Atrial fibrillation (= AF). A heart rhythm disorder where chambers in the upper heart (atria) beat more rapidly than those in the lower section of the heart.

The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe © Bayer AG, 2020 | Approval number ...

TUS pooled bzw. 2,1 %/Jahr in ROCKET AF). Die beobachteten Raten an schweren Blutungen (1,7 %/Jahr in XANTUS pooled bzw. 3,6 %/Jahr in ROCKET AF) waren gering. Bei den sekundären Endpunkten traten intrakranielle Blutungen selten auf (0,4 %/Jahr in XANTUS pooled bzw. 0,5 %/ Jahr in ROCKET AF) und gastrointestinale

In the XANTUS pooled analysis, a total of 11,121 patients were enrolled into the three real-world studies and included in the analysis. Patients were from 47 countries in Western Europe/ Canada/Israel (47.5%), Eastern Europe (23.2%), East Asia (20.1%), the Middle East/Africa (6.2%) and Latin America (3.0%).

XANTUS Pooled: Key Differences in Outcomes by Region Major bleeding Highest in Western Europe/Canada/Israel vs other regions (2.3 vs 0.7–1.6 events/ 100 patient-years) Stroke/non-CNS SE Highest in East Asia vs other regions (1.8 vs 0–1.0 events/ 100 patient-years) Mortality Highest in the Middle East/Africa and Latin America vs other regions

XANTUS pooled analysis real-world study The XANTUS (Xarelto for Prevention of Stroke in Patients with Atrial Fibrillation) programme has demonstrated the safety and effectiveness of rivaroxaban in the general population. XANTUS was a prospective, international, observational, non-interventional clinical study. The study was designed to ...

Patients with Atrial Fibrillation in Asia) and XANTUS-EL (Xarelto® for Prevention of Stroke in ... The XANTUS global program: pooled analysis of safety.

Separately, data from a pooled analysis of the Post-Marketing Safety Surveillance Study and the Xantus study (n=45,000) presented at the European Society of Cardiology conference confirmed that rates and patterns of major bleeding in patients taking rivaroxaban in routine clinical practice were low (2.89 and 2.1 per 100 person-years, respectively) and generally consistent with those observed ...

The purpose of this pooled analysis of the XANTUS, XANAP, and XANTUS-EL studies was to assess the global safety profile of rivaroxaban in routine clinical practice. Methods We performed a pre-planned pooled analysis of the studies in the XANTUS program (the XANTUS, XANAP, and XANTUS-EL studies).

PDF | On Aug 1, 2017, P. Kirchhof and others published P3592Safety analysis of rivaroxaban: a pooled analysis of the global XANTUS programme ...

XANTUS Pooled: Key Differences in Outcomes by Region Major bleeding Highest in Western Europe/Canada/Israel vs other regions (2.3 vs 0.7–1.6 events/ 100 patient-years) Stroke/non-CNS SE Highest in East Asia vs other regions (1.8 vs 0–1.0 events/ 100 patient-years) Mortality Highest in the Middle East/Africa and Latin America vs other regions

separately, data from a pooled analysis of the post-marketing safety surveillance study and the xantus study (n=45,000) presented at the european society of cardiology conference confirmed that rates and patterns of major bleeding in patients taking rivaroxaban in routine clinical practice were low (2.89 and 2.1 per 100 person-years, …

a Pooled Analysis of the Global XANTUS Programme (Real World, Prospective, Observational Studies for Stroke Prevention in Patients with Atrial Fibrillation) Objective 1 To assess the global safety profile of Xarelto in routine practice through a pooled analysis of studies in the XANTUS programme, collecting information on AF

XANTUS Pooled - Efficacité et sécurité du rivaroxaban en vie réelle. L’efficacité des anticoagulants oraux directs (AOD) a été bien établie dans le cadre des essais cliniques de phase 3, en prévention des accidents vasculaires cérébraux (AVC) et des embolies systémiques (ES) chez les patients ayant une fibrillation atriale non ...

Comprising a total of 11,121 patients, XANTUS pooled is the largest prospective, observational analysis of a single non-vitamin K oral ...

Safety Analysis of Xarelto®: a Pooled Analysis of the Global XANTUS Programme (Real World, Prospective, Observational Studies for Stroke ...

09.07.2018 · Comprising a total of 11,121 patients, XANTUS pooled is the largest prospective, observational analysis of a single non-vitamin K oral anticoagulant (NOAC) used for the prevention of stroke in patients with AF.

11.01.2022 · une analyse globalisée les caractéristiques démographiques et cliniques des patients inclus dans le programme xantus (xantus pooled) sont détaillées dans le tableau. à noter que les scores chads2 et cha2ds2-vasc étaient en moyenne de 2,0 ± 1,3 et 3,5 ± 1,7 respectivement, et le score has-bled de 2,0 ± 1,1, dans cette population âgée en moyenne …

Methods: A pre-planned pooled analysis of the XANTUS, XANAP (Xarelto for Prevention of Stroke in Patients With Atrial Fibrillation in Asia), ...

About XANTUS Pooled Analysis. This is a pre-planned pooled analysis of the prospective, observational XANTUS, XANAP and XANTUS-EL studies of unselected patients with AF newly starting rivaroxaban for stroke prevention. Patients were followed for 1 year, at ~3-month intervals, or for =30 days after permanent discontinuation.

XANTUS pooled: global rivaroxaban use in real-world patients with NVAF The XANTUS programme evaluated the safety and efficacy of rivaroxaban in real-world patients with NVAF across the globe © Bayer AG, 2020 | Approval number PP-XAR-ALL-0639-1 All Toggle dropdown ESC 2020 AF Diabetes Symposium (mobile optimized version)